F/M Investments’s Tarsus Pharmaceuticals TARS Stock Holding History

F/M Investments’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-39,240	Closed	-$3.21M	–	434
2025 Q4	$3.21M	Buy	+39,240	New	+$2.93M	0.12%	187

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

F/M Investments's TARS Position: Q1 2026 in Review

F/M Investments sold out of Tarsus Pharmaceuticals (TARS) in Q1 2026, closing a stake of 39,240 shares — an estimated $3.21M sold.

F/M Investments first reported a position in TARS in Q4 2025 and held it in 1 quarter. The position peaked at $3.21M in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

F/M Investments reported no remaining Tarsus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
F/M Investments sold 39,240 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $3.21M.
F/M Investments first reported a position in Tarsus Pharmaceuticals in Q4 2025 and held it in 1 quarter.
F/M Investments's Tarsus Pharmaceuticals position peaked at $3.21M in Q4 2025.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on F/M Investments's 13F filing for Q1 2026, filed 11 May 2026.